Duobrii (halobetasol propionate / tazarotene) topical lotion — coverage criteria
Customize your policy alerts
Sign up for Centene Policy CP PMN.208 alerts
Get alerted when Policy CP PMN.208 changes without checking for updates manually.
Monitor payer policy activity
Clinical policy governing medical necessity and prior authorization requirements for Duobrii (halobetasol propionate 0.01%/tazarotene 0.045%) topical lotion for treatment of plaque psoriasis in adults across Centene lines of business.
Step therapy bypass for Illinois HIM per IL HB 5395 added for certain requirements.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.